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Abstract: Nitric Oxide Reductase (NOR) is an integral membrane protein performing the reduction
of NO to N2O. NOR is composed of two subunits: the large one (NorB) is a bundle of 12
transmembrane helices (TMH). It contains a b type heme and a binuclear iron site, which is
believed to be the catalytic site, comprising a heme b and a non-hemic iron. The small subunit
(NorC) harbors a cytochrome c and is attached to the membrane through a unique TMH. With the
aim to perform structural and functional studies of NOR, we have immunized dromedaries with
NOR and produced several antibody fragments of the heavy chain (VHHs, also known as
nanobodiesTM). These fragments have been used to develop a faster NOR purification procedure,
to proceed to crystallization assays and to analyze the electron transfer of electron donors.
BIAcore experiments have revealed that up to three VHHs can bind concomitantly to NOR with
affinities in the nanomolar range. This is the first example of the use of VHHs with an integral
membrane protein. Our results indicate that VHHs are able to recognize with high affinity distinct
epitopes on this class of proteins, and can be used as versatile and valuable tool for purification,
functional study and crystallization of integral membrane proteins.
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Introduction
In the past 12 years, camelid VHH domains (or nano-
bodies)1,2 have been widely used for basic research
studies, as potential reagents3–7 or drugs.5,8–11 A wealth
of crystal structures against protein antigens4,12–22 or
haptens23,24 has revealed the amazing versatility of their
binding modes. They can recognize enzyme clefts (lyso-
zyme, amylase), use a unique CDR for providing inter-
actions, interact with haptens laterally, or use part of
their framework for proteins binding (amylase, etc). To
date, however, all the complexes reported were from
camelid Igs obtained through llama or dromedary im-
munization with soluble proteins.
During our study of the enzymes from the denitri-
fication cascade, catalyzing the reduction of NO3 to
N2,
25 we have undertaken experiments aiming at a
better understanding of Nitric Oxide Reductase
(NOR), the last of the four enzymes whose structure
still remains unknown.26–31 NOR is composed by two
subunits: NorB, a 12 transmembrane helix b-type cyto-
chrome harboring two heme groups and a non-heme
Fe center, and NorC, a membrane bound mono-hemic
c-type cytochrome25 (see Fig. 1). It catalyses the reduc-
tion of NO to N2O: 2NO þ 2e þ 2Hþ ! N2O þ H2O.
NOR resembles strikingly bacterial cytochrome c oxi-
dase (COX), which possess a Cu ion instead of the Fe
center32 in the catalytic site (see Fig. 1). NOR and
COX sequences are similar: Ps. nautica NOR (the
enzyme studied here) large subunit shares 56%
sequence identity (72% similarity) with the large subu-
nit of Paracoccus denitrificans COX, of known struc-
ture.32 On the basis of this similarity, it has been
proposed that they might be evolutionary related.33
With in mind to study Ps. nautica NOR structure
and function, we have immunized a dromedary with
the purified protein. We have obtained six VHHs
against this enzyme with four of them displaying Kd
values in the nM range. Using Surface Plasmon Reso-
nance (SPR) and electron transfer assays, we could
determine that several epitopes have been targeted.
These nanobodies are presently used as tools towards
Ps. nautica NOR crystallization. Finally, we report
here, for the first time, that the complete and efficient
procedure for immunization, VHHs selection and puri-
fication documented on soluble proteins can be
adapted readily to integral membrane proteins.
Results
NOR purification
The NOR two-subunits complex has been successfully
extracted and purified from DDM solubilized mem-
branes of Ps. nautica cells (Timóteo CG, et al. in prep-
aration). Calculated from the absorption measurement
at 410 nm, this procedure yielded 10 mg of purified
protein per 200 L of Ps. nautica fermentor culture.
Protein content, purity and homogeneity were esti-
mated by SDS-PAGE and MALDI-TOF mass spectrom-
etry. NorB, which is an integral membrane protein
with twelve predicted transmembrane helices, appears
on gel as a band with an apparent mass of 38 kDa,
smaller than the expected MW of 54.4 kDa, and it is
not detectable by mass spectrometry, as often noticed
with integral membrane proteins. NorC appears on gel
as a band of the expected MW (17.6 kDa) and in mass
spectrometry as a sharp symmetrical peak at the
expected MW, indicating the absence of proteolysis
(see Fig. 2). Purified protein in 100 mM K phosphate
buffer at pH 7.0 with 0.02% DDM and 0.01% phenyl
ethanol could be concentrated up to 30 mg/mL with
no evidence of aggregation. The electron transfer activ-
ity of purified NOR has been tested both with cyto-
chrome c552 and ascorbate as electron donors (see
later).
VHHs selection and production
Dromedary immunization was performed with purified
NOR. Lymphocytes were isolated from blood samples,
and a phage display library of the VHHs was generated
using standard procedures (see Methods). Recombi-
nant antibody fragments were selected from this phage
display library by panning against NOR. Six VHHs
binders (01, 02, 03, 15, 27, and 41) were obtained and
sequenced (see Fig. 3). Binder sequences were aligned
with the human POT vH35 and the dromedary
VHHLys3, an inhibitor of hen egg-white lysozyme.12
Several features confirm the heavy-chain antibody ori-
gin of the antigen-specific binders2: (1) they show sub-
stitutions Leu11Ser, Val37Phe/Tyr, Gly44Glu,
Figure 1. Schematic representation of nitric oxide
reductase (NOR, upper left) and cytochrome c oxidase
(COX, lower left). The heme groups and iron ions are
colored red and the copper ion blue. Right side: compact
model of Paracoccus denitrificans COX (1AR1).32 The large
subunit is green, the cytochrome c small subunit is orange,
and the VH domain from the bound Fv is yellow. [Color
figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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Leu45Arg, and Trp47Gly, characteristic of VHHs; (2)
the three hypervariable regions (CDRs), with the
exception of VHHn03, have an average length of the
CDR3 loop of 16 amino acids; (3) as frequently
observed in VHHs, all NOR binders excepted for
VHHn03 and VHHn41 contain two extra-cysteines in
CDR1 and CDR3 allowing the formation of an inter-
loop disulfide bond.
The six VHHs binders (01, 02, 03, 15, 27, and 41)
were expressed in the periplasm of E. coli WK6 as
fusion proteins, with a C-terminal His6-tag. After two
successive chromatographic steps, Ni affinity column
and gel filtration, the VHHs fragments were at least
95% pure, as judged by SDS-PAGE (see Fig. 4). The
purification yield varied between 0.5 and 9 mg/L of
culture, depending on the clone. All purified proteins
were monomeric, soluble and showed the expected
molecular mass on SDS-PAGE (see Fig. 4) and by
mass spectrometry.
NOR-VHH complexes purification and
characterization
NOR-VHH complexes were prepared in two different
ways. In the first protocol, purified NOR was mixed
with the appropriate VHH and separated from the
excess of VHH by gel filtration. In the second protocol,
the His-tagged recombinant VHHs were used as
powerful tool for the preparation and purification of
NOR-VHH complexes. A VHH was mixed directly with
Ps. nautica solubilized membrane fraction to form the
complex, which was further purified in two-steps, Ni
affinity-chromatography followed by gel filtration. This
last procedure for obtaining the complex is much
faster, since NOR has not to be prepurified. Moreover,
the yield and purity of the resulting NOR-VHH com-
plexes, analyzed by gel filtration chromatography,
SDS-PAGE, Western blot, MALDI-TOF mass spec-
trometry (see Fig. 2), and HPLC-Wyatt analysis, were
very satisfying. The complexes remained monodisperse
in DDM buffer for several weeks as judged by analyti-
cal gel filtration chromatography on HPLC-Wyatt. This
is illustrated in Figure 5 for the mass determination of
the complex NOR-VHHn03 in DDM: the total mass is
182 kDa. The molecular mass measured for the com-
plex is 87.6 kDa, which is close to the theoretical value
of 85.7 kDa (71.8 kDa for NOR and 13.9 kDa for
VHHn03), and indicates that NOR is present in solu-
tion as a monomer. The mass determined for the
Figure 3. Alignment of VHH amino-acid sequences (lysozyme and NOR binders) and of one vH human variable domain of
heavy chain (POT vH). The hypervariable regions (CDR) are shown in red, green and blue. Residues substitutions are in pink,
Cys residues involved in an intradomain (C22 and C92) are in orange, extra Cys residues possibly involved in an interloop
disulfide bond are in purple. Kabat numbering is used.34 [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
Figure 2. Characterization of NOR and its complex with VHHn03 a) SDS-PAGE and anti-His Western blot; Lane 1: MW
markers, lane 2: purified NOR, lane 3: purified NOR-VHHn03 complex, lane 4: purified VHHn03. b) MALDI-TOF mass
spectrometry analysis of NOR-VHHn03 complex.
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detergent is 100 kDa (see Fig. 5), indicating that
196 molecules of DDM (510.6 Da) maintain NOR in
solution. NOR-VHH complexes purified by either
method showed identical kinetic behavior (see enzy-
matic activity).
Affinity and epitope mapping of VHHs
We have determined the dissociation constants of the
VHH binders for NOR by Surface Plasmon Resonance
(SPR, BIAcore) experiments. Different VHHs were cova-
lently linked to a BIAcore CM5 chip by amine coupling.
We chose to attach the VHHs to the chip as they are
more stable than NOR, making, thus, easy the regenera-
tion procedure with ethylenglycol and/or SDS. Moreover,
the larger molecular mass of NOR makes it a more favor-
able candidate to be used as analyte. In a first step, the
equilibrium dissociation constants of five individual
VHH binders (01, 02, 03, 27, and 41) for NOR were
determined and found to be in the nanomolar range (1–
50 nM) (Table I). In a second step, epitope mapping of
the five VHHs versus VHHn03 was performed, using as
analyte the preformed binary complex of NOR with
VHHn03. The binary complex was able to bind only to
VHHn41 and VHHn27, with Kd values close to those
determined for NOR alone (7 and 5.8 nM for VHHn41
and 11 and 45 nM for VHHn27). These results clearly
show that VHHn03, VHHn41, and VHHn27 interact
with NOR at independent sites. As a positive control, the
preformed ternary complex NOR-VHHn03-VHHn41 was
passed as analyte over VHHn27 covalently bound. The
quaternary complex is formed; the affinity of VHHn27
for the ternary complex is two times higher than that for
the binary complex (5.9 and 11 nM) and one order of
magnitude higher than that for NOR alone (5.9 and
45 nM). On the basis of the results of these binding
experiments, we decided to use the binary, ternary, and
quaternary complexes in further crystallization trials.
Crystallization and X-ray diffraction
Conditions giving rise to diffracting crystals were not
found with NOR alone, at least in our hands. On the
basis of the experience of other laboratories and confi-
dent that complex formation with antibody fragments
Figure 4. SDS-PAGE of purified VHHn01, 02, 03, 15, 27
and 41 of respectively 15.3, 14.3, 13.5, 14.5, 15.0, and
14.7 kDa (Lane1: MM marker).
Figure 5. HPLC-Wyatt analysis of NOR-VHHn03 complex. The abscissa indicates the time scale of the HPLC injection, the
left ordinate indicates the molar mass in g/mol (Da) and the right ordinate the UV absorbance at 280 nm. Absorption peak is
in black and the curves indicating the molar mass for the complex in detergent, the protein alone and the detergent are in
red, green, and blue, respectively. [Color figure can be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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may facilitate the crystallization of membrane pro-
teins,32,36–38 we systematically used NOR-VHH binary,
ternary, and quaternary complexes for crystallization
trials. For each complex, excepted for the ternary
NOR-VHHn03 þ 41, we have obtained crystals, in
general after 2 weeks. Average resolution of the crys-
tals was between 12 and 6 Å. A preliminary data set
was collected at 7 Å resolution with NOR-VHHn02
crystals at the Swiss Light Source Synchrotron Radia-
tion Facility at the Paul Scherrer Institut (SLS, Swit-
zerland) beam line X10SA (PXII). Crystals belong to
space group P21 with cell dimensions a ¼ 85.0 Å, b ¼
135.3 Å, c ¼ 137.2Å, and b ¼ 95.6. The Vm values and
water percentages calculated for the asymmetric unit
are of 4.6 Å2/Da ¼ 73%, 3.1 Å2/Da ¼ 60%, and 2.3
Å2/Da ¼ 47%, for 2, 3, and 4 molecules, respectively.
Enzymatic activity
Reduced Ps. nautica cytochrome c552 or ascorbate/
PMS are efficient electron donors for NOR (Timóteo
CG, et al., in preparation), and were used to evaluate
the activity of NOR in complex with VHHs in compari-
son to the activity of NOR alone. All complexes are
active with ascorbate/PMS, although at different level
(see Fig. 6); NOR complexed with VHHn02 and
VHHn03 is inactive with reduced cytochrome c552 but
active with ascorbate/PMS. The binding of VHHn27
partially affects the kinetic behavior of NOR with c552
as electron donor, while VHHn41 scarcely modifies
activity in the presence of either electron donor system.
Discussion
We report for the first time camelid immunization and
VHHs selection against an integral membrane protein.
The VHHs obtained by this means can be used, as
Swiss knives, in a variety of situations: difficult protein
purification, functional studies, epitope mapping,
crystallization.
Using VHHs, we could purify NOR readily in two
chromatography steps and reduce the purification time
to two days. A similar approach was used for the first
time to purify COX with antibody fragments.39 In our
previous protocol, three chromatography steps were
necessary and the overall process lasted for 5 days. As
membrane proteins are often fragile and detergents
expensive, a shorter and faster purification may be
crucial for obtaining a stable preparation. The idea of
using VHHs for protein purification was also proposed
recently in the case of soluble proteins.7 As often
observed with the VHHs domains, five of the six anti-
gen-specific binders selected by panning could be
expressed in E. coli readily and in quantities sufficient
for BIAcore binding experiments, crystallization and
enzymatic assays. Four of these VHHs have excellent
Kd values, ranging from 1.3 to 9.2 nM, while a fifth
has a Kd value of 45 nM. The affinity values class these
VHHs among the best raised against soluble pro-
teins.4,12–22 The best binder, VHHn03 forms a strong
complex with NOR (1.3 nM). When the complex NOR-
VHHn03 was passed over the four other VHHs
attached to the BIAcore chip, two of them (VHHn01
and 02) did not interact with the complex, indicating
that they share the same epitope as VHHn03. In con-
trast, the two remaining VHHs (VHHn027 and 41)
interact with the complex, demonstrating that these
Table I. Kinetic Rate Constants and Equilibrium
Dissociation Constant of NOR Antibody Fragments as
Determined by BIAcore. Purified NOR or NOR in
Complex with VHHn Were Injected over the Sensor
Chip Coated with the Corresponding VHHn Fragments
kon10




VHHn01 0.7  0.2 6.2  1.2 9.2  1.1
VHHn02 1.4  0.3 6.7  1.6 5.2  1.7
VHHn03 1.5  0.3 1.8  0.2 1.3  0.25
VHHn41 1.1  0.35 5.6  2.0 5.8  1.6
VHHn27 0.3  0.1 15  6 45  5
NOR-VHHn03þ
VHHn01 nc nc nc
VHHn02 nc nc nc
VHHn03 nc nc nc
VHHn41 1.2  0.4 8.3  2.0 7.0  1.5
VHHn27 2.2  0.1 22  1.5 11  1.4
NOR-VHHn03-VHHn41þ
VHHn27 7  2 39  0.5 5.9  1.3
nc: not calculable.
Figure 6. Specific activity plot of different NOR-VHHn complexes using two electron donating systems (white—ascorbate/
PMS; grey—reduced Ps. nautica cytochrome c552).
Conrath et al. PROTEIN SCIENCE VOL 18:619—628 623
three binders have distinct epitopes. It should be
noticed that VHHn41 Kd value does not change signifi-
cantly when binding to NOR alone or to NOR-
VHHn03 complex, indicating that VHHn41 should
bind to an epitope quite distinct from that of
VHHn03. In contrast, when VHHn27 binds to the
NOR-VHHn03 complex, the Kd value decreases four-
fold as compared to the binding to NOR alone. We
propose, therefore, that VHHn27 binds to an epitope
distinct but close enough to that of VHHn03, and that
the association of VHHn03 to NOR may induce a con-
formational change favorable to the further binding
of VHHn27. The ternary complex NOR-VHHn03-
VHHn41 is still able to bind to the VHHn27, demon-
strating that VHHn41 and VHHn27 have also distinct
epitopes. The Kd of VHHn27 with NOR-VHHn03-
VHHn41 is slightly lower (1.7-fold) than with the bi-
nary complex, suggesting some limited effect (confor-
mational or steric) of VHHn41 on the subsequent
binding by VHHn27.
It is interesting to know the location of the four
VHH binders epitopes on NOR. To this end, we meas-
ured the electron transfer activity of NOR with ascor-
bate/PMS or cytochrome c552 as electron donors in
presence of four VHHs. When the bulky dimeric cyto-
chrome c552
40 is used as electron donor, electron
transfer is abolished by VHHn02 and VHHn03. This
means that the epitope common to both VHHs coin-
cides with the reduced cytochrome c552 binding site on
NorC subunit, and that these VHHs prevent cyto-
chrome c552 to transfer electrons to NOR. In contrast,
when the small molecules of ascorbate and PMS are
used in the experiments, electron transfer is not
altered by any of the VHHs, meaning that they can
sneak into the cytochrome domain close to the heme
iron. Alternatively, ascorbate and PMS may bypass the
cytochrome c552 electron delivery pathway and deliver
electrons to the active site through a different mecha-
nism that is not blocked by the VHHs. Torndycroft
et al.41 also consider this possibility based on the in-
formation that ascorbate/PMS can also effectively
deliver electrons to other classes of NORs which lack
the c subunit.42
In contrast to VHHn02 and VHHn03, VHHn27
alters partially (by 60%) the electron transfer, which
suggests that they interact partially with reduced cyto-
chrome c552. BIAcore experiments have confirmed that
VHHn27 binding site is different to that common to
VHHn02 and VHHn03, the presence of which abolish
completely cytochrome c552 binding. Therefore
VHHn27 should not interact at all with the VHHn02
or VHHn03, but should interact partially with the
large dimeric cytochrome c552 that binds at the same
place as VHHn02 or VHHn03.
In conclusion, neither of the small VHHn02 nor
VHHn03 molecules interfere with the VHHn27 bind-
ing site, while the large dimeric cytochrome c552 does.
The binding of VHHn41 does not alter significantly the
electron transfer by reduced cytochrome c552. Consid-
ering the respective sizes of VHHs and cytochrome
c552 and that of the NorC subunit (as estimated from
COX in Fig. 1), it is very likely that two or even three
VHHs, such as VHHn02, VHHn27, and VHHn41, that
we found able to co-crystallize with NOR, can bind
simultaneously on NorC subunit (Fig. 1, right). The
VHHn41, however, might also bind to a completely
different epitope, on the cytochrome c small subunit
side, or even internally.
It is well-established that binders favor protein
crystallization, particularly that of integral membrane
proteins.32,38 In this later case, they may help by pro-
viding nondetergent covered protein surfaces, favor-
able to tight packing, or by stabilizing the flexible
membrane protein in a given conformation.38 This has
been illustrated with COX, a topological relative of
NOR,32 with the b2-adrenergic receptor38 and in sev-
eral other cases. Here we have shown that all our com-
plexes of VHHs with NOR crystallize readily, while
NOR alone does not, despite several years of intensive
efforts. However, most crystals diffract to 6 Å at best.
We expect that further optimizations will make it pos-




(Sigma), DEAE-Biogel A gel ion exchange (Bio-rad),
Macroprep Ceramic hydroxyapatite type I and Bio-
Scale CHT20-I column (Ceramic hydroxyapatite type
I) (BioRad), Ni-NTA column, 6xHis ladder and penta-
His-HRP conjugate (Qiagen), ECL chemiluminescent
detection system, Superdex 75 column, His-trap crude
FF column (GE Healthcare), PVDF membranes
(Roche), bicinchoninic acid (BCA) protein assay kit
(Pierce), Amicon-Ultra cutoff 10–50 kDa concentrators
(Millipore).
Ps. nautica NOR (NORn) production
Ps. nautica cells were grown as described by Prudên-
cio et al.43 Ps. nautica medium culture contained: 11.7
g/L NaCl, 12.3 g/L MgSO47H2O, 0.75 g/L KCl, 6.05 g/
L Tris, 3 g/L NH4Cl, 2 mL sodium lactate 60%, 1 g/L
Yeast-Extract, 1 g/L KNO3, 2 mg/L FeSO47H2O, 74.4
mg/L K2HPO4, 1.47 g/L CaCl22H2O, 1 ml/L Starkey
oligo-elements stock solution pH7.5. 1000 oligo-
elements stock solution: 263 mM MgO, 20 mM
CaCO3, 22.3 mM FeSO47H2O, 5 mM ZnSO47H2O,
3.6 mM MnSO4H2O, 0.1 mM CuSO45H2O, 3.2 mM
CoSO47H2O, 0.97 mM BO3H3, 0.8 mM Mo7(N-
H4)6(O2)44H2O, 0.14 mM Ni(NO3)26H2O, 0.12 mM
Na2SeO3. A volume of 200 ml of medium, inoculated
with a 20 mL Ps. nautica overnight culture, were first
grown in bottle under aerobic conditions at 30C. The
200 ml culture was used to inoculate 2 L of medium
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and let grown 24 hours under anaerobic conditions to
reach an OD600 of 0.8. This 2 L culture was used to
inoculate 18 L of medium and let grown 5 hours under
aerobic conditions (air supply of 0.2 volume per vol-
ume per minute) and 19 hours under anaerobic condi-
tions to reach an OD600 of 0.8. Volume of 200 L of
medium in a 300 L working volume fermentor
(CHEMAP) was finally inoculated with this 18 L cul-
ture and grown again at 30C 5 hours under aerobic
conditions (air supply of 0.2 v/v per minute) and 19
hours under anaerobic conditions. Cells were har-
vested by centrifugation at 14000g at 4C under N2
atmosphere (100 L/h). Resulted 250 g wet pellet was
resuspended in 1 L 10 mM Tris pH 7.2, disintegrated
(1.8 Kbars) and stored aliquoted at 20C.
Ps. nautica NOR purification
NOR was purified as described by Timóteo C. G. et al.
(manuscript in preparation): 250 mL of defrost Ps
nautica fermentor pellet (corresponding to 50 L of
culture) were diluted two times in 50 mM Tris pH8.0
at 4C and ultracentrifuged 1H30 at 40,000 rpm, 4C.
Pellets were resuspended in 500 mL 50 mM Tris pH
8.0, 100 mM KCl with a Potter-S homogenizer
(Braun). Protein concentration was quantified follow-
ing the BCA method using bovine serum albumin as a
standard and brought to a concentration of 10 mg/ml.
Resuspended pellets were sonicated, washed two times
in 50 mM Tris pH 8.0 by ultracentrifugation 1H30 at
40,000 rpm, 4C, aliquoted in 3  250 mL at 10
mg/ml and stored at 80C. Solubilization of mem-
branes from 250 mL defrost sample was done by addi-
tion of 0.6% (w/v) n-dodecyl-b-D-maltopyranoside
(DDM) and 0.01% (v/v) S-sec-phenyl-ethyl alcohol
(phenyl ethanol) 15 min at 4C under agitation and
membrane proteins were recovered in supernatant af-
ter ultracentrifugation 1H30 at 40,000 rpm, 4C. Sam-
ple was applied on DEAE column equilibrated in 50
mM Tris pH 8.0, 0.02% DDM, 0.01% phenyl ethanol.
After washing the column, elution of NOR protein by
a linear gradient from 0 to 500 mM NaCl was fol-
lowed spectrophotometrically at 410 and 278 nm ab-
sorbance. Eluate was buffer exchanged and concen-
trated in 10 mM K phosphate pH 7.0, 400 mM NaCl,
0.02% DDM, 0.01%, phenyl ethanol (buffer A), ali-
quoted in 3  20 mL and stored at 80C. A 20 mL
defrost sample was brought to 0.1% DDM and centri-
fuged 15 min at 7000g before being applied on a Mac-
roprep hydroxyapatite column equilibrated in buffer A.
A gradient from 0 to 100% of buffer B (1.5M K phos-
phate pH 7.0, 0.02% DDM, 0.01% phenyl ethanol)
was applied to the column and eluted fractions were
pooled, buffer exchanged and concentrated in buffer
A. Pool was brought again to 0.1% DDM and centri-
fuged 15 min at 7000g before being applied on a Bio-
Scale hydroxyapatite column equilibrated in buffer A.
A gradient from 0 to 100% of buffer B was applied to
the column. Eluted fractions were pooled, buffer
exchanged and concentrated in 100 mM K phosphate
pH 7.0, 0.02% DDM, 0.01% phenyl ethanol. Purified
NOR concentration was determined spectrophotomet-
rically from absorbance at 410 nm.
Dromedary immunization, VHH library
construction, and binders selection
A dromedary was injected subcutaneously on days 0,
7, 14, 21, 28, 35 with about 500 lg (per injection) of
purified NOR in Gerbu adjuvant. On day 39, anticoa-
gulated blood was collected from the vein for the prep-
aration of lymphocytes.
The lymphocytes from the ‘immune’ blood were
purified on Lymphoprep. The total RNA from the
peripheral blood lymphocytes was extracted and used
as template for first strand cDNA synthesis with oligo
(dT) primer. Using this cDNA, the VHH encoding
sequences were amplified by PCR according to Saerens
et al.,44 digested with PstI and NotI, and cloned into
the PstI and NotI sites of the phage-display phagemid
vector pHEN4.45 A VHH library of about 4  107 inde-
pendent transformants was obtained. About 82% of
these transformants harbored the vector with an insert
corresponding to the expected VHH gene size. Three
consecutive rounds of phage display and panning (1011
phages per well of microtiter plate) were performed on
solid-phase coated NOR (100 lg/mL, 10 lg/well). The
enrichment for antigen-specific phages within the
pools at each round of panning was assessed by poly-
clonal phage ELISA. A clear enrichment was seen after
the second and third round of panning. Totally 96
individual colonies (48 from 2nd round and 48
from third round) were randomly selected and ana-
lyzed by ELISA for the presence of antigen specific
VHHs in their periplasmic extracts. The VHH sequen-
ces from the ELISA-positive colonies were subject to
RFLP analysis using HinfI restriction enzyme and nu-
cleotide sequencing. Seven different nanobodies were
identified.
VHHs expression and purification
VHH genes of the binders were sequenced and subcl-
oned in pHEN6 vector in fusion with pelB sequence
on N-ter and six histidine tag on C-ter.46 Escherichia
coli WK6 cells transformed with the appropriate vector
were grown at 37C in Terrific Broth medium contain-
ing 100 lg/mL ampicillin and 0.1% glucose until opti-
cal density reached 0.8. Expression was induced by
the addition of 1 mM IPTG and growth was continued
for an additional 16 hours at 28C. Periplasmic frac-
tion containing the VHH fragments was prepared.47
The His-tail-containing fusion protein was purified by
immobilized metal affinity chromatography on a 5 mL
Ni-NTA column in 50 mM Na/K phosphate pH 8.0,
300 mM NaCl, 10% glycerol. Eluted fractions in 250
mM imidazole were concentrated on a Amicon-Ultra
10 kDa cutoff concentrator prior to be loaded on a
HiLoad 10/30 Superdex75 PG gel filtration column in
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PBS. Protein concentration of the VHHs was deter-
mined by UV spectrometry from absorbance at 278
nm, using their calculated extinction coefficient.
NOR-VHHs complexes purification
NOR–VHH complexes were prepared following two
different procedures.
1 Purified NOR in 100 mM KPB (potassium phos-
phate buffer) pH 7.0, 0.02% DDM, 0.01%, phenyl
ethanol (PE) was incubated with pure VHH protein
in PBS pH 7.2, for 1 h on ice, in a 1:1.2 molar ratio.
NOR-VHH complex was purified and separated
from free antibody excess by gel filtration chroma-
tography on a Superdex75 column in 100 mM KPB
pH 7.0, 0.005% (w/v) DDM, 0.01% (v/v) PE.
2 Solubilized protein from membrane fraction (see
NOR purification (Timóteo CG, et al. in preparation)
was dialyzed against 100 mM KPB pH 7.0, 0.02%
DDM, 0.01% PE and incubated with pure VHH (in
the same buffer), in 1:1.2 ratio for 1 h. The mixture
was applied onto a His-trap FF crude column (GE
Healthcare) equilibrated in the same buffer. The col-
umn was washed with 60 mM imidazole and eluted
with 250 mM imidazole in the same buffer. Eluted
fractions were pooled and concentrated. When
necessary the complex was mixed with one or two
additional distinct VHH. NOR-VHH complex was
separated from free antibody excess by gel filtration
chromatography as described in 1. NOR-VHH con-
centration was determined using NOR extinction
coefficients (e411 nm ¼ 295 mM1 cm1) (Timóteo
CG, et al. in preparation) and purity was evaluated
by SDS-PAGE.
NOR-VHHs complexes characterization
Western blot. Proteins were transferred from a
15% SDS-PAGE gel to a Hybond PVDF membrane and
blocked with 5% nonfat dried milk in 20 mM Tris-HCl
pH 7.6, 150 mM NaCl, 0.1% Tween 20 at 4C. The
membrane was then treated with anti His-HRP pri-
mary antibodies. Visualization of VHH-specific bands
was done by ECL chemiluminiscence.
Mass spectrometry. Mass spectrometry was per-
formed on a matrix-assisted laser desorption/ioniza-
tion time of flight (MALDI-TOF) mass spectrometer
(Bruker Autoflex, Bruker Daltonics, Bremen, Germany)
according to standard procedures, slightly modified for
membrane proteins.
MALS/UV/RI (Wyatt). Size exclusion chromatog-
raphy was performed on an Alliance 2695 HPLC sys-
tem (Waters) using a Silica Gel KW804 column (Sho-
dex) eluted with 50 mM Tris-HCl pH 8, 300 mM
NaCl, 0.05% DDM at a flow rate of 0.5 mL/min.
30 lL sample between 0.5 and 1 mg/mL was routinely
applied on the column. Detection was performed using
a triple-angle light scattering detector (Mini-DAWNTM
TREOS, Wyatt technology, Sanata Barbara, USA). Mo-
lecular weight determination was performed by ASTRA
V software (Wyatt technology).
SPR affinity measurements
Kinetic analysis of NOR-VHHs interactions were per-
formed on BIAcore 1000 using CM5 (carboxymethy-
lated dextran) sensor chip coated with 500–900 reso-
nance units of individual purified VHH fragments
immobilized by amine coupling. VHHs non-specific
for NOR were used as control. For the kinetic con-
stants determination, diluted solutions of NOR or
NOR in complex with VHHs (0.3–40 nM in 10 mM
Hepes pH 7.2, 150 mM NaCl, 2 mM EDTA, 0.005%
surfactant P20) were passed over the flow-cell with
the specific VHHs and on the control flow-cell. Bind-
ing traces were recorded for at least five concentra-
tions of analyte, in triplicate. Each binding-regenera-
tion cycle was performed at room temperature with a
constant flow rate of 40 lL/min. In each cycle, buffer
(50 lL) was injected first to stabilize the baseline, the
analyte (80 lL) was then injected and the spontaneous
dissociation was followed for 6 min; regeneration of
the binding surface was achieved by injection of 5 lL
of ethylenglycol and/or 0.5% SDS and further washing
with the running buffer for 6 min. Curves obtained
after subtraction of the reference and the buffer sig-
nals were fitted to a (1:1) Langmuir binding model and
a (1:1) binding with mass transfer with BIAevaluation
(BIAcore). Better results, in terms of chi2 and stand-
ard error of the calculated values, were obtained with
the first model.
Crystallization and X-ray diffraction
Initial crystallization screening of NOR-VHHs com-
plexes were performed with commercial kits Mem-
Start, MemSys, MemGold I and II, MemPlus (Molecu-
lar Dimensions Ltd), MB I and II (QIAGE). The
nanodrops experiments were carried out with a Carte-
sian HoneyBee X8 robot, using sitting-drops in
Greiner plates (100–200-300) nL of protein mixed
with 100 nL of well solution). In the first round of
crystallization trials, the concentration of binary
(NOR-VHHn02, NOR-VHHn03, NOR-VHHn27 and
NOR-VHHn41), ternary (NOR-VHHn03 þ 27 and
NOR-VHHn03 þ 41) and quaternary (NOR-VHHn03
þ 27 þ 41) complex varied between 3 and 12 mg/mL
in the purification buffer 100 mM potassium phos-
phate pH 7.0, 0.01% phenyl ethanol, 0.005% DDM.
Kinetic activity assays
NO reductase activity measurements were performed
as described by Timóteo CG, et al. (manuscript in
preparation). Purified NOR was incubated for 30 min
on ice with each or mixtures of VHHs in equimolar
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ratio (1:1). After incubation, the complexes were
assayed for NO reductase activity with ascorbate/PMS
or reduced Ps. nautica cytochrome c552 as electron
donors.
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